Welcome to our dedicated page for Longboard Pharmaceuticals news (Ticker: LBPH), a resource for investors and traders seeking the latest updates and insights on Longboard Pharmaceuticals stock.
Longboard Pharmaceuticals, Inc. (LBPH) is a clinical-stage biopharmaceutical company pioneering novel therapies for rare neurological disorders. This dedicated news hub provides investors and industry stakeholders with timely updates on corporate developments, research breakthroughs, and regulatory progress.
Access authoritative information on LBPH's innovative pipeline, including program-specific updates across their portfolio of optimized neurological therapeutics. The resource consolidates official press releases, clinical trial milestones, and strategic partnership announcements in one centralized location.
Key content categories include updates on drug candidate development, regulatory filings, scientific presentations, and corporate governance matters. All materials maintain factual accuracy while avoiding speculative commentary to support informed decision-making.
Bookmark this page for streamlined access to verified LBPH developments. Check regularly for updates on their mission to advance transformative treatments for complex neurological conditions through precision pharmacology.
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (LBPH) announces the presentation of Phase 1b/2a clinical data from the PACIFIC Study on bexicaserin at the AAN Annual Meeting and EILAT XVII. The study evaluates the drug in patients with DEEs, showcasing its efficacy and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.39%
Tags
-
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) granted inducement awards to three new employees, offering 99,500 non-qualified stock options. The options have an exercise price of $21.60 per share, vesting over time. This move aims to attract and retain top talent in the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.39%
Tags
-
News
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. reports positive topline data from the Phase 1b/2a PACIFIC Study for bexicaserin (LP352) in participants with DEEs, showcasing significant seizure reductions. The company plans to initiate a global Phase 3 program by YE 2024 and expects to present PACIFIC data at medical meetings in Q2 2024. Additionally, the Phase 1 SAD study for LP659 is on track, with financial results indicating a strong cash position after a successful public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.05%
Tags
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (LBPH) granted inducement awards to four new employees in the form of non-qualified stock options. The options allow the purchase of 184,000 shares of Common Stock at an exercise price of $22.18 per share. The options vest over time, with 25% becoming exercisable after one year and the remaining 75% in monthly installments over 36 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
-
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (LBPH) granted inducement awards to five new employees in the form of non-qualified stock options to purchase 145,475 shares of its common stock. The options were granted on January 31, 2024, with an exercise price of $21.24 per share. Vesting is structured with 25% on the one-year anniversary of employment start date and the remaining 75% in 36 monthly installments, contingent on continued employment. The grants were approved by the Compensation Committee and are in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
-
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (LBPH) announced that its senior leadership team will present at two investor conferences in February. The company will participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 7, 2024, and the Oppenheimer 34th Annual Healthcare Life Sciences Virtual Conference on February 14, 2024. The presentations will be available via live webcasts on the company's website and will be archived for at least 30 days after the events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (LBPH) announced the closing of its underwritten public offering of 11,500,000 shares of its voting common stock, grossing approximately $241.5 million. The offering was made pursuant to two shelf registration statements on Form S-3, including base prospectuses, previously filed with the SEC. Cantor and Citigroup acted as joint lead book-running managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.77%
Tags
-
Rhea-AI Summary
Longboard Pharmaceuticals, a clinical-stage biopharmaceutical company (Nasdaq: LBPH), announced the pricing of an upsized underwritten public offering of 10,000,000 shares of its voting common stock at $21.00 per share. The gross proceeds are expected to be $210.0 million. The offering is expected to close on January 8, 2024. Cantor and Citigroup are acting as joint lead book-running managers for the offering. The offering is being made pursuant to two shelf registration statements on Form S-3, including base prospectuses, previously filed with the SEC and declared effective on October 11, 2022 and August 11, 2023, respectively, as well as a related registration statement on Form S-3MEF.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.94%
Tags
-
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) has announced a proposed underwritten public offering to issue and sell $150 million of shares of its voting common stock, with a 30-day option to purchase up to an additional approximately $22.5 million of shares. Cantor and Citigroup are acting as joint lead book-running managers for the offering, with Wedbush PacGrow and H.C. Wainwright & Co. as lead managers. The offering is being made pursuant to two shelf registration statements on Form S-3, declared effective on October 11, 2022 and August 11, 2023. A preliminary prospectus supplement will be filed with the SEC and will be available for free on the SEC’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.76%
Tags
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) announced positive topline data from the PACIFIC Study evaluating bexicaserin (LP352), a potentially best-in-class and highly selective, oral, novel 5-HT2C receptor superagonist for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs). The study showed a median seizure reduction of 53.3% in countable motor seizures compared to 20.8% in the placebo group across the DEE study population, with favorable safety and tolerability results. Longboard is rapidly moving forward with preparations for its global Phase 3 program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
316.25%
Tags
Longboard Pharmaceuticals, Inc.
Nasdaq:LBPH
LBPH Rankings
LBPH Stock Data
2.34B
33.87M
1.2%
121.42%
4.94%
Biotechnology
Pharmaceutical Preparations
United States
LA JOLLA